Drug/Small Molecule:
gentamicin

Overview

Trade Names: Alcomicin; Apogen; Bristagen; G-Mycin; G-Myticin; Garamycin; Garamycin Otic Solution; Genoptic Liquifilm; Genoptic S.O.P.; Gentacidin; Gentafair; Gentak; Gentamar; Gentamcin Sulfate; Jenamicin; Ocu-Mycin; Spectro-Genta; U-gencin
Brand Mixtures: Diprogen Crm (Betamethasone Dipropionate + Gentamicin Sulfate); Diprogen Ont (Betamethasone Dipropionate + Gentamicin Sulfate); Garasone Oph/Ot Sol (Betamethasone + Gentamicin Sulfate); Garasone Ophthalmic Ointment (Betamethasone + Gentamicin Sulfate); Gentamicin Sulfate in Nacl 0.9% Inj (Gentamicin Sulfate + Sodium Chloride); Gentocin Durafilm (Betamethasone 21-Acetate + Gentamicin Sulfate); Gentocin Otic Solution (Betamethasone + Gentamicin Sulfate); Otomax Ointment (Betamethasone + Clotrimazole + Gentamicin Sulfate); Sandoz Pentasone (Betamethasone + Gentamicin Sulfate); Topagen Ont (Betamethasone + Gentamicin Sulfate); Topagen Spray (Betamethasone + Gentamicin Sulfate); Valisone G Cream (Betamethasone + Gentamicin Sulfate); Valisone G Ointment (Betamethasone + Gentamicin Sulfate)
PharmGKB Accession Id: PA449753

Description

A complex of three different closely related aminoglycoside sulfates, Gentamicins C1, C2, and C1(subA), obtained from Micromonospora purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit protein synthesis (genetic translation). PubChem (source: Drug Bank)

Indication

For treatment of serious infections caused by susceptible strains of the following microorganisms: <i>P. aeruginosa</i>, <i>Proteus</i> species (indole-positive and indole-negative), <i>E. coli</i>, <i>Klebsiella-Enterobactor-Serratia</i> species, <i>Citrobacter</i> species and <i>Staphylococcus</i> species (coagulase-positive and coagulase-negative). (source: Drug Bank)

ATC Therapeutic Categories

  • D06AX:Other antibiotics for topical use
  • J01GB:Other aminoglycosides
  • S01AA:Antibiotics
  • S02AA:Antiinfectives
  • S03AA:Antiinfectives

Pharmacology, Interactions, and Contraindications

Mechanism Of Action

Aminoglycosides like gentamicin "irreversibly" bind to specific 30S-subunit proteins and 16S rRNA. Specifically gentamicin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes. (source: Drug Bank)

Pharmacology

Gentamicin is a broad spectrum aminoglycoside antibiotic. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. In addition, some mycobacteria, including the bacteria that cause tuberculosis, are susceptible to aminoglycosides. Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, but other types of antibiotics are more potent and less damaging to the host. In the past the aminoglycosides have been used in conjunction with penicillin-related antibiotics in streptococcal infections for their synergistic effects, particularly in endocarditis. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses. (source: Drug Bank)

Absorption, Distribution, Metabolism, Elimination & Toxicity

Protein Binding

Low (between 0 and 30%) (source: Drug Bank)

Absorption

Injections lead to peak serum concentrations in 30-60 minutes. Topical gentamicin is readily absorbed from large burned, denuded, or granulating areas but not through intact skin. Absorption of gentamicin is faster and greater with the cream compared to the ointment. Gentamicin is absorbed in small quantities following topical application to the eye. Gentamicin is also absorbed in small amounts following topical application to the ear (especially if the eardrum is perforated or if tissue damage is present). (source: Drug Bank)

Toxicity

Mouse, intravenous LD<sub>50</sub>: 52 mg/kg; rat, intravenous LD<sub>50</sub>: 96 mg/kg. (source: Drug Bank)

Isomeric SMILES Code:

C[C@H]([C@@H]1CC[C@H]([C@@H](O1)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@H]3[C@@H]([C@H]([C@](CO3)(C)O)NC)O)N)N)N)NC (source: Drug Bank)

The following genes are in curated knowledge about this drug.

  Gene Relationship Evidence
No phenotype data No genotype data Literature annotations available Not annotated
MT-TT
  • CO
  •   
  •   
  •   
  • GN
Publications

A list of non-curated publications that mention this drug along with other genes is available.

Drug Targets

Gene Description
LRP2 Uncurated Annotation (source: Drug Bank)

A list of non-curated publications that mention this drug along with other drugs is available.

Drug Interactions

Drug Description
atracurium Uncurated Annotation The agent increases the effect of muscle relaxant (source: Drug Bank)
bumetanide Uncurated Annotation Increased ototoxicity (source: Drug Bank)
cefalotin Uncurated Annotation Increased risk of nephrotoxicity (source: Drug Bank)
cefamandole Uncurated Annotation Increased risk of nephrotoxicity (source: Drug Bank)
cefazolin Uncurated Annotation Increased risk of nephrotoxicity (source: Drug Bank)
cefonicid Uncurated Annotation Increased risk of nephrotoxicity (source: Drug Bank)
cefoperazone Uncurated Annotation Increased risk of nephrotoxicity (source: Drug Bank)
ceforanide Uncurated Annotation Increased risk of nephrotoxicity (source: Drug Bank)
cefotaxime Uncurated Annotation Increased risk of nephrotoxicity (source: Drug Bank)
cefotetan Uncurated Annotation Increased risk of nephrotoxicity (source: Drug Bank)
cefoxitin Uncurated Annotation Increased risk of nephrotoxicity (source: Drug Bank)
cefradine Uncurated Annotation Increased risk of nephrotoxicity (source: Drug Bank)
ceftazidime Uncurated Annotation Increased risk of nephrotoxicity (source: Drug Bank)
ceftizoxime Uncurated Annotation Increased risk of nephrotoxicity (source: Drug Bank)
ceftriaxone Uncurated Annotation Increased risk of nephrotoxicity (source: Drug Bank)
cefuroxime Uncurated Annotation Increased risk of nephrotoxicity (source: Drug Bank)
cephapirin Uncurated Annotation Increased risk of nephrotoxicity (source: Drug Bank)
cisplatin Uncurated Annotation Increased risk of nephrotoxicity (source: Drug Bank)
doxacurium Uncurated Annotation The agent increases the effect of muscle relaxant (source: Drug Bank)
ethacrynic acid Uncurated Annotation Increased ototoxicity (source: Drug Bank)
furosemide Uncurated Annotation Increased ototoxicity (source: Drug Bank)
gallamine triethiodide Uncurated Annotation The agent increases the effect of muscle relaxant (source: Drug Bank)
metocurine Uncurated Annotation The agent increases the effect of muscle relaxant (source: Drug Bank)
mivacurium Uncurated Annotation The agent increases the effect of muscle relaxant (source: Drug Bank)
pancuronium Uncurated Annotation The agent increases the effect of muscle relaxant (source: Drug Bank)
pipecuronium Uncurated Annotation The agent increases the effect of muscle relaxant (source: Drug Bank)
rocuronium Uncurated Annotation The agent increases the effect of muscle relaxant (source: Drug Bank)
succinylcholine Uncurated Annotation The agent increases the effect of muscle relaxant (source: Drug Bank)
thalidomide Uncurated Annotation Thalidomide increases the renal toxicity of the aminoglycoside (source: Drug Bank)
torasemide Uncurated Annotation Increased ototoxicity (source: Drug Bank)
tubocurarine Uncurated Annotation The agent increases the effect of muscle relaxant (source: Drug Bank)
vecuronium Uncurated Annotation The agent increases the effect of muscle relaxant (source: Drug Bank)

Curated Information

The following diseases are in curated knowledge about this drug.

  Disease Relationship Evidence
No phenotype data No genotype data Literature annotations available Not annotated
Ototoxicity
  • CO
  •   
  •   
  •   
  • GN
Publications

Non-Curated Information

A list of non-curated publications that mention this drug along with other diseases is available.

LinkOuts

Web Resource:
Wikipedia
DrugBank:
DB00798
ChEBI ID:
17833
KEGG Compound ID:
C00505
PubChem Compound ID:
3467
PubChem Substance ID:
3788
IUPHAR Ligand ID:
2427

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Non-Curated Publications

A list of non-curated publications that mention this drug is available.

PharmGKB integrates drug information from different sources: DrugBank, Open Eye Scientific Software.
Add New Alternate Name
Add New ATC Term
Add Cross Reference
Add a metabolite
Add a text annotation
Add a drug target
hint: enter a gene
    Add a drug interaction
    hint: enter a drug
    PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (GM61374).
    ©2001-2010 PharmGKB.